Intravitreal triamcinolone acetonide for the management of papillophlebitis and associated macular edema.
BACKGROUND
To investigate the efficacy of intravitreal injection of triamcinolone acetonide in the management of papillophlebitis and associated cystoid macular edema.


METHODS
This study was a retrospective medical records review of four eyes of four patients (three males and one female) who had approximately 2-4 months history of papillophlebitis and associated persistent cystoid macular edema. These patients were treated with a single intravitreal injection of 4 mg triamcinolone acetonide. Mean follow-up time was 15 +/- 4 months. The outcome measures included best corrected visual acuity (BCVA), intraocular pressure (IOP), and central retinal thickness by optical coherence tomography (OCT).


RESULTS
The BCVA ranged from 20/100 to 20/60 pre-operation. The mean gain in BCVA was 7 +/- 1 Snellen lines. All eyes had BCVA of 20/20 at the last visit. The mean baseline central retinal thickness as measured by OCT was 529 +/- 53 microm. The mean central retinal thickness by OCT was 235 +/- 15 microm at 1-week follow-up examination. At the last visit the mean central retinal thickness by OCT was 161 +/- 7 microm. One patient experienced an increase in IOP after the first injection and another patient had IOP elevation after the second injection. Both were well controlled with single topical anti-glaucoma medication.


CONCLUSIONS
Intravitreal injection of triamcinolone acetonide appears to be an effective treatment for patients with papillophlebitis and associated cystoid macular edema.
Chang
Yo-Chen
YC
Department of Ophthalmology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Wu
Wen-Chuan
WC
D000328:Adult; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009898:Optic Disk / Q000098:blood supply*; D009901:Optic Nerve Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D010689:Phlebitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012169:Retinal Vein; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide
Acta Ophthalmol (Copenh). 1984 Oct;62(5):780-6
6507065
Arch Ophthalmol. 2004 Aug;122(8):1131-6
15302652
J Glaucoma. 2001 Aug;10(4):284-7
11558812
Retina. 2001;21(5):408-15
11642369
Retina. 2005 Oct-Nov;25(7):846-50
16205562
Br J Ophthalmol. 1972 Sep;56(9):652-70
4653856
Am J Ophthalmol. 2001 Sep;132(3):425-7
11530068
Arch Ophthalmol. 1992 Aug;110(8):1155-9
1497531
Br J Ophthalmol. 1971 Nov;55(11):721-33
5129964
Arch Ophthalmol. 2004 Mar;122(3):317-21
15006842
Ophthalmology. 2001 Apr;108(4):765-72
11297495
Br J Ophthalmol. 2003 Sep;87(9):1126-9
12928281
Eye Ear Nose Throat Mon. 1966 Oct;45(10):62 passim
5920162
Am J Ophthalmol. 2005 May;139(5):860-6
15860292
Am J Ophthalmol. 1980 Dec;90(6):810-6
7446668
Ann Neurol. 1978 May;3(5):438-40
727723
Retina. 1992;12(1):3-11
1565869
Br J Ophthalmol. 1961 Dec;45(12):778-88
18170737